Section Arrow
APLT.NASDAQ
- Applied Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2025/09/02 08:19 EDT
Pre Market
Last
 0.47
-0.0227 (-4.61%)
Bid
0.4891
Ask
0.4927
High 0.4927 
Low 0.4479 
Volume 37198 
Regular Hours
Last
 0.4927
-0.0186 (-3.64%)
Day High 
0.5137 
Prev. Close
0.5113 
1-M High
0.5335 
Volume 
505.79K 
Bid
0.4891
Ask
0.4927
Day Low
0.4908 
Open
0.505 
1-M Low
0.4011 
Market Cap 
73.63M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.51 
20-SMA 0.48 
50-SMA 0.43 
52-W High 10.6237 
52-W Low 0.295 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.46/-0.32
Enterprise Value
76.02M
Balance Sheet
Book Value Per Share
0.12
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
455.00K
Operating Revenue Per Share
0.07
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CARMCarisma Therapeutics0.215-0.013-5.70%-- 
Pre Market 0.5313 +0.3163 +147.12%
TNFATNF Pharmaceuticals Inc.0.0483-0.0133-21.59%-- 
Pre Market -- -- --
ADAPAdaptimmune Therapeutics plc0.0589-0.01-14.51%-- 
Pre Market 0.0594 +0.0005 +0.85%
SRPTSarepta Therapeutics18.2-0.14-0.76%15.76PE
Pre Market 17.86 -0.34 -1.87%
OTLKOutlook Therapeutics0.8512-0.2388-21.91%0.58PE
Pre Market 0.86 +0.0088 +1.03%
Quotes are at least 15-min delayed:2025/09/02 08:19 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.